OncoCyte Corp (OCX)

HEALTH CARE: HEALTH CARE SUPPLIES
SIC: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

15 CUSHING IRVINE, CA 92618

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. The Company's tests and services present multiple opportunities to advance cancer care while also driving revenue growth for the Company. Oncocyte has launched DetermaRx™, a test that identifies early-stage lung cancer patients who are at high risk for cancer recurrence post-resection and predicts benefit from adjuvant chemotherapy. Oncocyte has also launched DetermaIO™, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, as a research use only tool for pharmaceutical and academic clinical trials. To complement DetermaIO™, the company anticipates launching DetermaTx™, a test to assess mutational status of a tumor to help identify the appropriate targeted therapy, in the second half of 2021. The Company previously announced its planned acquisition of Chronix Biomedical Inc. and its TheraSure™ CNI Monitor test, and also plans to continue with the development of DetermaMx™ as the Company seeks to expand into the blood-based monitoring market. Oncocyte's pharmaceutical services provide pharmaceutical companies who are developing new cancer treatments a full suite of molecular testing services to support the drug development process.

Data as of 2021-09-11 11:35:46 -0400
Market Cap359.916 Million Shares Outstanding91.582 Million Avg 30-day Volume525.744 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS0
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-0.55 Enterprise Value
Total Cash Current Debt Gross Profit
BETA2.06821 52-week High/Low6.57 / 1.2 Next Earnings Date2021-11-11 Price to Cash FLow (P/CF) -49.1758
Data provided by IEX Cloud
View SEC Filings from OCX instead.

View recent insider trading info

Funds Holding OCX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding OCX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

ANDREWS RONALD ASBURY CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
243,212 2021-07-01 4

KINGSLEY ALFRED D

  • Director
55,000 2021-06-24 4

REDMOND CAVAN M.

  • Director
55,000 2021-06-24 2

ARNO ANDREW

  • Director
55,000 2021-06-24 2

LAST ANDREW J.

  • Director
55,000 2021-06-24 3

GRIFFITH MELINDA

  • Director
55,000 2021-06-24 1

CARTER JENNIFER L.

  • Director
55,000 2021-06-24 1

YU LI VP CNTRLLR/PRNCPL ACCTNG OFFCR

  • Officer
0 2021-05-18 1

LEVINE MITCHELL S CHIEF FINANCIAL OFFICER

  • Officer
62,080 2021-04-28 3

SUNDAR PADMAVATHI CHIEF COMMERCIAL OFFICER

  • Officer
255,000 2021-02-25 2

ROSS DOUGLAS T. CHIEF MEDICAL OFFICER

  • Officer
255,000 2021-02-25 2

BROADWOOD PARTNERS, L.P.

BROADWOOD CAPITAL INC

BRADSHER NEAL C

  • 10% Owner
33,556,113 2021-02-05 1

HESTERBERG LYNDAL K. CSO

  • Officer
7,477 2020-12-11 1

PARKER ALBERT P COO

  • Officer
10,586 2020-12-11 1

KALAJIAN TONY T SR.VP/CHIEF ACCOUNTING OFFICER

  • Officer
15,000 2020-08-03 0

PURA VIDA INVESTMENTS, LLC

KAMEN EFREM

  • 10% Owner
12,223,953 2020-01-20 0

LINEAGE CELL THERAPEUTICS, INC.

  • PREVIOUS 10% OWNER
No longer subject to file 2020-01-02 0

MOHANTY ADITYA P.

  • Director
0 2019-07-19 0

ANNETT WILLIAM PRESIDENT AND CEO

  • Officer
  • Director
0 2019-03-14 0

ANDREWS RONALD ASBURY

ANDREWS RONALD ASBURY

  • Director
34,964 2018-08-30 4

MECHEM KRISTINE C. VP OF MARKETING

  • Officer
0 2018-06-07 0

BAILEY DON M

  • Director
247,001 2017-06-15 0

WEST MICHAEL D

  • Director
0 2016-02-16 0

CHAPMAN KAREN B. VICE PRESIDENT OF RESEARCH

  • Officer
0 2016-02-16 0

SEGALL JUDITH CORPORATE SECRETARY

  • Officer
29,657 2015-12-30 0

KARFUNKEL GEORGE

  • 10% Owner
3,659,860 2015-12-30 0

SKIBSTED RUSSELL CHIEF FINANCIAL OFFICER

  • Officer
0 2015-12-30 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ONCOCYTE CORP OCX 2021-09-17 22:15:03 UTC -0.2306 0.3006 2300000
ONCOCYTE CORP OCX 2021-09-17 21:45:03 UTC -0.2306 0.3006 2300000
ONCOCYTE CORP OCX 2021-09-17 21:15:04 UTC -0.2306 0.3006 2300000
ONCOCYTE CORP OCX 2021-09-17 20:45:03 UTC -0.2366 0.3066 2300000
ONCOCYTE CORP OCX 2021-09-17 20:15:05 UTC -0.2366 0.3066 2300000
ONCOCYTE CORP OCX 2021-09-17 19:45:03 UTC -0.2366 0.3066 2300000
ONCOCYTE CORP OCX 2021-09-17 19:15:03 UTC -0.2366 0.3066 2300000
ONCOCYTE CORP OCX 2021-09-17 18:45:03 UTC -0.2366 0.3066 2300000
ONCOCYTE CORP OCX 2021-09-17 18:15:03 UTC -0.2366 0.3066 2300000
ONCOCYTE CORP OCX 2021-09-17 17:45:03 UTC -0.2366 0.3066 2300000
ONCOCYTE CORP OCX 2021-09-17 17:15:03 UTC -0.2366 0.3066 2300000
ONCOCYTE CORP OCX 2021-09-17 16:45:03 UTC -0.2459 0.3159 2300000
ONCOCYTE CORP OCX 2021-09-17 16:15:02 UTC -0.2459 0.3159 2300000
ONCOCYTE CORP OCX 2021-09-17 15:45:02 UTC -0.2459 0.3159 2300000
ONCOCYTE CORP OCX 2021-09-17 15:15:03 UTC -0.2459 0.3159 2300000
ONCOCYTE CORP OCX 2021-09-17 14:45:03 UTC -0.2442 0.3142 2300000
ONCOCYTE CORP OCX 2021-09-17 14:15:03 UTC -0.2442 0.3142 2300000
ONCOCYTE CORP OCX 2021-09-17 13:45:02 UTC -0.2442 0.3142 2300000
ONCOCYTE CORP OCX 2021-09-17 13:15:03 UTC -0.2442 0.3142 2300000
ONCOCYTE CORP OCX 2021-09-17 12:45:03 UTC -0.2442 0.3142 2300000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund OCX -34700.0 shares, $-178358.0 2021-04-30 N-PORT
RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund OCX -4680.0 shares, $-26863.2 2021-06-30 N-PORT

Elevate your investments